The Future of Ketamine and Mood Disorders In 2019, the FDA and European Fee approved using an esketamine nasal spready underneath the brand name Spravato to treat depression. Nevertheless, as of 2021, ketamine has not been approved with the FDA to deal with depression or other mental overall health disorders, https://julianc952hkl1.wikilima.com/user